Key result
Review highlights anaplerosis as a key therapeutic target to sustain cardiac energy metabolism in HF.
Why the study?
Underlying cellular mechanisms in heart failure remain poorly understood, and alterations in cardiac anaplerosis offer potential therapeutic targets for addressing energy deficiency.
Answers are grounded in this paper and cite their sources.
Modulating anaplerosis presents a potential therapeutic strategy to address energy deficiency and rescue the failing heart in heart failure patients.
Heart failure (HF) is a complex syndrome and a leading cause of mortality worldwide. While current medical treatment is based on known pathophysiology and is effective for many patients, the underlying cellular mechanisms are poorly understood. Energy deficiency is a characteristic of HF, marked by complex alterations in metabolism. Within the tricarboxylic acid cycle, anaplerosis emerges as an essential metabolic process responsible for replenishing lost intermediates, thereby playing a crucial role in sustaining energy metabolism and consequently cardiac function. Alterations in cardiac anaplerosis are commonly observed in HF, demonstrating potential for therapeutic intervention. This review discusses recent advances in understanding the anaplerotic adaptations that occur in HF. We also explore therapeutics that can directly modulate anaplerosis or are likely to confer cardioprotective effects through anaplerosis, which could potentially be implemented to rescue the failing heart.
No takes yet. Share an insight, caveat, or question.
Alhasan et al. (2024) conducted a review in Heart failure. Therapeutics modulating anaplerosis was evaluated. This review highlights the essential role of anaplerosis in sustaining cardiac energy metabolism in heart failure and explores potential therapeutics that modulate this process.
Synapse has enriched 10 related papers. Consider them for comparative context: